Immix Biopharma(US:IMMX) Globenewswire·2025-09-08 20:05Core Insights - Immix Biopharma, Inc. has received a strategic investment from Goose Capital and Dr. Nancy T. Chang, which is expected to enhance its development of cell therapies for AL Amyloidosis and other serious diseases [1][3] Company Overview - Immix Biopharma is a clinical-stage biopharmaceutical company focused on developing cell therapies, particularly its lead candidate NXC-201, a BCMA-targeted CAR-T cell therapy [5] - NXC-201 is currently being evaluated in a U.S. multi-center study for relapsed/refractory AL Amyloidosis, with interim results indicating that the primary endpoint was met [5] - The therapy has received Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug Designation (ODD) from the FDA and EMA [5] Investment Details - Goose Capital, an investment firm composed of former Fortune 500 executives and industry leaders, aims to invest in breakthrough technologies and innovative founders [4] - Dr. Nancy T. Chang, known for her role in developing FDA-approved drugs generating over $5 billion in sales, is a founding member of Goose Capital [2][4] Strategic Goals - The partnership between Immix and Goose Capital is aligned with the mission to commercialize NXC-201 and address unmet medical needs in AL Amyloidosis and other serious diseases [3] - Immix's leadership emphasizes the importance of Goose's experience in drug commercialization to achieve their goal of delivering accessible cures [3]